DLTH
Duluth Holdings Inc.
DLTH has a slight edge over LCID overall, supported by lower modeled downside.
LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
DLTH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
DLTH's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
DLTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $1.88 | -52% |
| Fair | 18x | $2.66 | -32% |
| Current | 26x | $3.90 | — |
| Expensive | 29x | $4.40 | +13% |
Historical ranges are pointers, not guarantees.
DLTH's PE is in its expensive range at 26x.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
DLTH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect DLTH's losses to shrink, with revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
DLTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.15 | +$1.52 |
| Q2 2026 | -$0.31 | +$1.21 |
| Q1 2026 | -$0.47 | +$0.84 |
| Q4 2025 | -$0.81 | +$0.17 |
| Q3 2025 | -$1.37 | -$0.92 |
| Q2 2025 | -$1.52 | -$1.12 |
| Q1 2025 | -$1.31 | -$1.03 |
| Q4 2024 | -$0.98 | -$0.71 |
DLTH has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
DLTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $121.4M | -7.8% |
| Q2 2026 | $98.6M | -4% |
| Q1 2026 | $215.9M | -11% |
| Q4 2025 | $114.9M | -9.6% |
| Q3 2025 | $131.7M | -7% |
| Q2 2025 | $102.7M | -12% |
| Q1 2025 | $241.3M | -1.8% |
| Q4 2024 | $127.1M | -8.1% |
DLTH's revenue has slid since its 2022 peak: $121M last quarter, down 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +14 points |
| Q2 2026 | -9.4% | +2.7 points |
| Q1 2026 | 4% | +4.6 points |
| Q4 2025 | -7.7% | +10 points |
| Q3 2025 | 1.8% | +4.6 points |
| Q2 2025 | -12% | -4.3 points |
| Q1 2025 | -0.6% | -4.5 points |
| Q4 2024 | -18% | -8.8 points |
DLTH has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over DLTH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
DLTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.2M | -5.5% |
| Q2 2026 | -$15.2M | +$42.6M |
| Q1 2026 | $53.5M | +38% |
| Q4 2025 | -$8.9M | +$34.8M |
| Q3 2025 | $29.8M | +99% |
| Q2 2025 | -$57.8M | -$22.6M |
| Q1 2025 | $38.7M | -36% |
| Q4 2024 | -$43.7M | -$5.5M |
DLTH has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
DLTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | 5.4x | High |
| Q4 2024 | 4.7x | High |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | 0.3x | Very low |
| Q1 2024 | -1.3x | Net Cash |
DLTH has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DLTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 44.2 | Neutral |
DLTH's weekly RSI is 50 (neutral) and its Stochastic is 44 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
DLTH PE vs Consumer Cyclical Sector
| Metric | DLTH | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 18x | 44% above |
| PE % | 73 | 47 | 26 pts above |
DLTH is trading at 26x earnings, a 44% premium to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
DLTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.99 | 2.3% below |
| 20 week MA | $4.11 | 5.1% below |
| 50 week MA | $3.40 | 15% above |
| 100 week MA | $2.98 | 31% above |
| 200 week MA | $4.03 | 3.2% below |
DLTH has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
DLTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $11.2 | +8.6% |
| 2021 | $11.2 | $15.1 | +35% |
| 2022 | $15.1 | $5.90 | -61% |
| 2023 | $5.90 | $5.38 | -8.8% |
| 2024 | $5.38 | $3.03 | -44% |
| 2025 | $3.03 | $2.11 | -30% |
| 2026 YTD | $2.11 | $3.90 | +85% |
DLTH has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.